Citizens Maintains Market Outperform on IRulya Therapeutics, Raises Price Target to $86
Citizens analyst Jonathan Wolleben maintains IRulya Therapeutics (NASDAQ:IRLA) with a Market Outperform and raises the price target from $77 to $86.
Last updated: 2026-11-19 07:27:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
IRulya Therapeutics Inc. (IRLA) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $40.67, with a market capitalization of $416.85M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $25.13 to $45.00. This page covers its latest market performance, valuation, price trends and company information.
$416.85M | |
$37.94 | |
$42.28 | |
$37.94 | |
$38.45 | |
116.50K | |
102.31K | |
-- | |
$45.00 | |
$25.13 | |
-- | |
2026-06-30 |
IRulya Therapeutics Inc. (IRLA) last closed at $40.67 as of 2026-11-19 00:31:00, up 6.63% ($2.55) from the previous close of $38.45.
During the latest regular trading session, IRLA traded between $37.94 and $42.28, with a volume of 116.50K shares. The closing price was near the middle and near the upper end of its 52-week range.
Over the past seven days, IRulya Therapeutics Inc. (IRLA) moved from $38.62 to $40.67, representing a gain of 5.31% ($2.05).
The stock traded between $32.57 and $45.00 during the period. The latest price is near the middle of the 7-day range, indicating strong upward.
The average daily volume was 141.63 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 78.2%
IRLA is currently trading at $40.67, placing it 78.2% of the way from its 52-week low of $25.13 to its 52-week high of $45.00. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
IRulya Therapeutics Inc is committed to transforming the lives of patients with serious, underserved diseases by developing disease-modifying therapies. The company is currently developing LAM-001 for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD), bronchiolitis obliterans syndrome post-lung transplant (BOS), and sarcoidosis-associated pulmonary hypertension (SAPH). A Phase 2a study in PH patients has been completed; a Phase 2 clinical study in BOS patients is ongoing; a Phase 2b clinical study in PH-ILD is ongoing; and a Phase 2 clinical study in SAPH is ongoing.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 38 |
| Exchange | NASDAQ |
| Company Website |
Latest news related to IRulya Therapeutics Inc. and IRLA stock.
Citizens analyst Jonathan Wolleben maintains IRulya Therapeutics (NASDAQ:IRLA) with a Market Outperform and raises the price target from $77 to $86.
IRulya Therapeutics (NASDAQ:IRLA) reported quarterly losses of $(2.31) per share which beat the analyst consensus estimate of $(19.83) by 88.35 percent. This is a 95.36 percent increase over losses of $(49.83) per share
Eligible investors can buy real shares of IRulya Therapeutics Inc. (IRLA) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to IRLA, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between IRLA shares and USD.
IRLA Shares to USD
1.00 IRLA shares = 40.67 USD
Calculations are estimates based on the latest available price and are for reference only.